Companies › Vigonvita Life Sciences
4 active drug programs in 7 registered trials: 6 Phase 1, 1 Phase 2; Other, Psychiatry; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| LV232 | – | Phase 2 | MDD | Sep 2027 |
| VV913 | – | Phase 1 | Healthy Volunteers | Dec 2026 |
| VV119 | – | Phase 1 | Schizophrenia; Healthy Volunteers | – |
| VV261 | – | Phase 1 | Healthy Volunteers | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07302269 | VV261 | Phase 1 | Healthy Volunteers | Other | Jun 2026 |
| NCT07372703 | VV913 | Phase 1 | Healthy Volunteers | Other | Sep 2026 |
| NCT06504290 | VV119 | Phase 1 | Schizophrenia | Psychiatry | Oct 2026 |
| NCT06105151 | VV119 | Phase 1 | Schizophrenia | Psychiatry | Oct 2026 |
| NCT07240636 | VV119 | Phase 1 | Healthy Volunteers | Other | Oct 2026 |
| NCT07565792 | VV913 | Phase 1 | Healthy Volunteers | Other | Dec 2026 |
| NCT06828887 | LV232 | Phase 2 | MDD | Psychiatry | Sep 2027 |
No annotated target.
–
Nanjing Minova Pharmaceutical Tortugas Neuroscience Syndeio Biosciences Clear Scientific Basilea Pharmaceutica
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.